Is Enovix (ENVX) Starting To Look Interesting After Recent Share Price Slide?

• If you are wondering whether Enovix at around US$4.92 is starting to look interesting or still too risky for your portfolio, this article will help you size up what you are really paying for.
• The share price has been under pressure, with returns of a 2.6% decline over 7 days, 21.7% decline over 30 days, 37.6% decline year to date, 31.8% decline over 1 year, 54.7% decline over 3 years and 67.4% decline over 5 years.
• Recent coverage has focused on Enovix's position in advanced battery technology and its progress in moving from development toward broader commercial deployment. This has kept investor attention on how fast the business model might scale. At the same time, funding needs, execution milestones and timelines for ramping production have been key talking points that frame how investors think about risk and reward around the stock.
• Simply Wall St currently gives Enovix a valuation score of 2 out of 6. Next we will compare different valuation approaches to that score before finishing with an even more complete way to think about what the stock might be worth.

Enovix scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Enovix Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and then discounts them back to today’s dollars to arrive at an intrinsic value per share.

For Enovix, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $174.74 million, so the focus is on what future cash generation could look like rather than current profitability.

Analyst and extrapolated projections see free cash flow moving from projected losses of $171.02 million in 2026 and $158.68 million in 2027 to a positive $83.15 million in 2028, with further positive figures projected out to 2035. All of these cash flows are expressed in dollars and are below $1 billion, so they sit firmly in the millions range.

When those projected cash flows are discounted back, Simply Wall St’s DCF model arrives at an estimated intrinsic value of about $15.10 per share. Against a current share price around $4.92, this output suggests the stock is 67.4% undervalued based on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Enovix is undervalued by 67.4%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Enovix.

Approach 2: Enovix Price vs Sales

For companies where earnings are not yet positive, the P/S ratio is often more useful than P/E because it compares the value the market places on the business to its current revenue base rather than profits that are not yet in place.

What counts as a reasonable P/S depends on how quickly revenue is expected to grow and how risky the path to that growth looks. Higher growth potential and lower perceived risk can support a higher multiple, while slower growth or higher uncertainty usually points to a lower, more conservative range.

Enovix is trading on a P/S of 32.75x, compared with the Electrical industry average of 2.35x and a peer group average of 17.45x. The current multiple is therefore well above both benchmarks. Simply Wall St’s Fair Ratio for Enovix is 3.63x. This is its proprietary estimate of what the P/S might be given factors such as earnings growth assumptions, industry, profit margin, market cap and company specific risks.

This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for those company specific drivers rather than assuming all firms deserve similar multiples.

On this basis, Enovix’s actual P/S of 32.75x is materially higher than the 3.63x Fair Ratio.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Enovix Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, which are simply your own story for Enovix that links what you think about its smartphone, defense and smart eyewear opportunities to a set of revenue, margin and earnings estimates, then to a Fair Value you can compare to the current price. All of this happens within the Simply Wall St Community page where millions of investors share views. You might see one Narrative that lines up with a higher Fair Value around US$76.53 based on very strong growth assumptions and another closer to US$10.00 with more cautious expectations. Both of these update automatically as new earnings, guidance or product news comes in and give you a clear, numbers backed way to decide whether you see the stock as attractively priced or not.

Do you think there's more to the story for Enovix? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com